Analysed MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ) News Sources
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
06-10-2026
yahoo.com
Is Rezdiffra’s Genetic-Risk Agnostic Data Reframing The Investment Case For Madrigal Pharmaceuticals (MDGL)?
07-10-2026
yahoo.com
Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year Run
08-10-2026
yahoo.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
15-10-2026
yahoo.com
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
19-10-2026
yahoo.com
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
20-10-2026
yahoo.com
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
27-10-2026
yahoo.com
What is the current price of MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ)?
The current price of MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ) is $430.36.
MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ) absolute price change since previous trading day?
The absolute price change of MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ) since the previous trading day is $-1.34.
MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ) percentage price change since previous trading day?
The percentage price change of MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ) since the previous trading day is -0.3104%.
What is the most recent average sentiment score for MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ)?
The most recent average sentiment score for MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ)?
The most recent sentiment for MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ) is .
SEC-8K** Filing Available For MADRIGAL PHARMACEUTICALS INC (MDGL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.